Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.
Camille DomergueElodie MartinCamille LemariéPascal JézéquelJean-Sébastien FrenelPaule AugereauMario CamponeAnne PatsourisPublished in: Cancers (2022)
In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- ejection fraction
- locally advanced
- chronic kidney disease
- newly diagnosed
- poor prognosis
- lymph node
- prognostic factors
- sentinel lymph node
- electronic health record
- big data
- squamous cell carcinoma
- radiation therapy
- early stage
- long non coding rna
- artificial intelligence